Dr. Chew is currently Chief Medical Officer Advisor to CorMedix which develops novel taurolidine-based therapeutics and Chief Medical Officer Advisor to Phesi which expedites clinical trials through innovative data-driven platforms. Dr. Chew's previous experience also includes the emerging area of digital health therapeutics when he was Chief Medical Officer for Omada Health.
Before joining Omada Health, Dr. Paul Chew was Senior Vice-President and Global Chief Medical Officer at Sanofi where he was responsible for the clinical development of innovative therapies for cardiovascular disease and diabetes. In several roles at Sanofi, Dr. Chew worked closely with payers, patient groups, and the full range of healthcare stakeholders. In addition, he is currently a member of the PhRMA Science & Regulatory Affairs Executive Committee and the Institute of Medicine Value & Science-Driven Healthcare Roundtable. Prior to Sanofi, US, Dr. Chew was Vice-President, Global Head of Metabolism and Diabetes at Aventis Pharmaceuticals, 2001-2004. Prior to joining Aventis, Dr. Chew was at the Bristol-Myers Squibb Company, starting in 1992 as Medical Director of Clinical Cardiovascular Development. Dr. Chew held numerous positions of increasing R&D responsibility at BMS; Dr. Chew was Vice President, U.S. Medical Affairs from 1999-2001 where he was responsible for Plavix, Avapro, Glucophage, and Pravachol.
Prior to his industry experience, Dr. Chew was Assistant Professor of Medicine at The Johns Hopkins Hospital, Attending Physician in Radiology, Director of the Pacemaker Clinic and a member of the Interventional Cardiology staff. His research interests included acute interventional cardiology, cardiac biomechanics, and statistical modeling of pericardial biomechanics. Dr. Chew obtained his medical education at The Johns Hopkins School of Medicine, serving his internal medicine training and cardiology fellowship at The Johns Hopkins Hospital. Dr. Chew is board-certified in Internal Medicine and Cardiovascular Diseases.